Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.

After a 233.1% total return over the past five years, Medpace Holdings now trades in a zone where the Discounted Cash Flow (DCF) intrinsic value estimate points to a roughly fair price, while traditional market multiples screen the stock as expensive. That combination leaves Medpace looking less like a clear bargain and more like a stock where expectations need to be checked carefully. Over five years, Medpace Holdings has returned 233.1%, which puts extra focus on whether current buyers are...

In the past few days, Medpace Holdings reported Q2 results that exceeded analyst revenue expectations and raised its full-year revenue guidance. The company also delivered the fastest revenue growth and largest guidance increase among its peers, highlighting its current operational momentum within the sector. Next, we’ll examine how Medpace’s upgraded full-year revenue guidance may influence the existing investment narrative around growth sustainability. The latest GPUs need a type of rare...

Why Medpace Holdings Stock Is Back in Focus After Q2 Results Medpace Holdings (MEDP) drew fresh attention after reporting Q2 earnings that beat revenue expectations and came with a higher full year revenue outlook, alongside the strongest revenue growth and guidance raise among peers. See our latest analysis for Medpace Holdings. Medpace Holdings has seen its share price pull back slightly in the past week, although a 30 day share price return of 7.6% and a 90 day share price return of 37.8%...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Medpace (NASDAQ:MEDP) and its peers.

Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.

Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%.

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Here is how ALX Oncology Holdings Inc. (ALXO) and Medpace (MEDP) have performed compared to their sector so far this year.

CON vs. MEDP: Which Stock Is the Better Value Option?

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

Medpace pairs double-digit growth, record awards and a strong balance sheet with a rich valuation, raising the question of whether the premium already prices in its outlook.

Medpace posted record Q2 awards and a stronger book-to-bill ratio, but can backlog conversion and study timing turn renewed demand into stronger 2027 growth?

Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.

Companies with more cash than debt often have stronger financial flexibility, making them attractive in uncertain markets. With interest payments less of a worry, these businesses can invest more in growth, innovation, or buybacks and dividends.

Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.

In July 2026, Medpace Holdings reported second-quarter results showing year-over-year increases in revenue and net income, and subsequently raised its 2026 guidance to forecast total revenue of US$2.81 billion–US$2.89 billion and net income of US$494 million–US$514 million, alongside updated earnings per diluted share of US$17.25–US$17.95. The company also reported record net new business awards, a backlog of about US$3.00 billion, and completed a sizeable share repurchase program totaling...

Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

Medpace Holdings Inc (MEDP) reports a robust 17.2% revenue increase and a 34.5% rise in net income, driven by a strong business environment and strategic shifts in program focus.

Thermo Fisher stock led a medtech rebound Thursday, easing investors' fears of continued malaise for the medical research and tools realm.

Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) jumped 14.4% in the afternoon session after the company reported second-quarter financial results that exceeded Wall Street's expectations. GAAP earnings per share came in at $4.25, surpassing analyst estimates of $3.99. Revenue reached $707.3 million, beating the consensus estimate of $689.7 million and marking a 17.2% increase year on year. Additionally, the company's adjusted EBITDA was $153.4 million, topping forecasts of $14

Medpace (NASDAQ:MEDP) reported double-digit growth in second-quarter revenue and earnings, while management described the business environment as strong and said lower cancellations helped drive record net bookings. CEO August Troendle said on the company’s second-quarter 2026 earnings call that ca

Moby summary of Medpace Holdings, Inc.'s Q2 2026 earnings call

Medpace (MEDP) delivered earnings and revenue surprises of +4.17% and +1.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medpace Holdings stock surged by double digits late Wednesday, helped by a big bookings beat, rebounding from a poor start to the year. Then, the book-to-bill ratio came in at 0.88x and Medpace stock plummeted to a nine-month low. In after-hours trades on the stock market today, Medpace stock zipped up 19% to 628.50.

Clinical research company Medpace Holdings (NASDAQ:MEDP) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 17.2% year on year to $707.3 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 2.6% above analysts’ estimates. Its GAAP profit of $4.25 per share was 6.6% above analysts’ consensus estimates.

Clinical research company Medpace Holdings (NASDAQ:MEDP) will be reporting earnings this Wednesday after market hours. Here’s what investors should know.

CON vs. MEDP: Which Stock Is the Better Value Option?

Medpace (MEDP) closed at $530.19 in the latest trading session, marking a -1.49% move from the prior day.